Antiresorptive Medication Use Is not Associated With Acute Cardiovascular Risk: An Observational Study
Authors' conclusion
oBP and Dmab use was not associated with CVEs.
Study context
- Population
- Participants with incident minimal trauma fracture from the Sax Institute's 45 and Up Study, NSW, Australia, followed 2005/2009 to 2017880 oral bisphosphonate (oBP) and 770 denosumab (Dmab) matched pairs
- Exposure
- oBP or DMAB use vs never users
- Outcome
- CVE (acute MI, unstable angina, cerebrovascular accident, transient ischemic attack)
- Follow-up
- ∼4.3 years
Methodological detailspropensity-score matched, stratified Cox's proportional hazards model
- Propensity-score matched
- Stratified Cox's proportional hazards model
Main finding
As reported in the abstract
CVE
Each group vs NoRxHazard ratio (95% CI)
oBPwomen
0.88(0.65–1.18)
oBPmen
1.07(0.72–1.57)
Dmabwomen
1.08(0.78–1.50)
Dmabmen
1.55(0.96–2.48)
Observational data: associations, not effects.
Original publication
Antiresorptive Medication Use Is not Associated With Acute Cardiovascular Risk: An Observational Study. J Clin Endocrinol Metab. Published 21 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →